NeoProfen

NeoProfen is a brand name of ibuprofen, approved by the FDA in the following formulation(s):

NEOPROFEN (ibuprofen lysine - injectable; intravenous)

• 
  Manufacturer: LUNDBECK INC
  
  Approval date: April 13, 2006
  
  Strength(s): EQ 20MG BASE/2ML (EQ 10MG BASE/ML) ^[RLD]

Has a generic version of NeoProfen been approved?

No. There is currently no therapeutically equivalent version of NeoProfen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of NeoProfen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
  Patent 6,342,530
  Issued: January 29, 2002
  Inventor(s): Laszlo; Darko
  Assignee(s): Farmacon-Il, LLC
  Pharmaceutical compositions are disclosed suitable for parenteral administration having anti-inflammatory, analgesic, and anti-pyretic properties, which consist of a therapeutically effective amount of d,l or l-lysine salt of R,S or S-ibuprofen as active ingredient dissolved in sterile water to form a solution in the absence of an inert atmosphere and either substantially free or absolutely free of any excipient, organic solvent, buffer, acid, base, salt other than the active ingredient and capable of storage in the absence of an inert atmosphere. Also disclosed are methods employing the new compositions in the treatment of pain and inflammation, in reducing fever and in treating patent ductus arterious or intraventricular hemorrhage in prematurely born neonates.
  
  Patent expiration dates:
  
  
  • November 14, 2020
    
    ✓ 
    Patent use: CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
    ✓ 
    Drug product
  
  
  
  • November 14, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATENT DUCTUS ARTERIOSUS
    ✓ 
    Drug product
  
  



• 
  Method of preventing retinopathy of prematurity in a neonate
  Patent 6,344,479
  Issued: February 5, 2002
  Inventor(s): Bart; Van Overmeire & Laszlo; Darko
  Assignee(s): Farmacon-Il, LLC
  A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate.
  
  Patent expiration dates:
  
  
  • March 20, 2021
    
    ✓ 
    Patent use: CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 13, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Neoprofen Intravenous Advanced Consumer Information (Micromedex)
• Ibuprofen Consumer Information (Drugs.com)
• Ibuprofen Consumer Information (Wolters Kluwer)
• Ibuprofen Capsules Consumer Information (Wolters Kluwer)
• Ibuprofen Chewable Tablets Consumer Information (Wolters Kluwer)
• Ibuprofen Drops Consumer Information (Wolters Kluwer)
• Ibuprofen Injection Consumer Information (Wolters Kluwer)
• Ibuprofen Suspension Consumer Information (Wolters Kluwer)
• Children's Ibuprofen Berry Consumer Information (Cerner Multum)
• Ibuprofen Consumer Information (Cerner Multum)
• Bufen Advanced Consumer Information (Micromedex)
• Equate Children's Ibuprofen - Berry - Dye Free Advanced Consumer Information (Micromedex)
• I-Prin Advanced Consumer Information (Micromedex)
• Midol Advanced Consumer Information (Micromedex)
• Proprinal Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Berry Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Bubble Gum Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Grape Advanced Consumer Information (Micromedex)
• Ibuprofen Advanced Consumer Information (Micromedex)
• Ibuprofen Intravenous Advanced Consumer Information (Micromedex)
• Ibuprofen lysine Intravenous Advanced Consumer Information (Micromedex)
• Ibuprofen AHFS DI Monographs (ASHP)